Literature Scan
Efficacy of Eltrombopag
in Patients With Lower-
Risk Myelodysplastic
Syndromes and
Thrombocytopenia
Platelet transfusions are commonly administered
to patients with myelodysplastic syndromes (MDS)
who develop profound thrombocytopenia, but the
short therapeutic effect and eventual transfusion
refractoriness have prompted researchers to look for
new treatment options.
In a study published in the Lancet Haematology,
Esther N. Oliva, MD, from the Division of Hematol-
ogy at Azienda Ospedaliera Bianchi-Melacrino-Morelli
in Reggio Calabria, Italy, and co-authors assessed the
safety and efficacy of eltrombopag, an oral thrombo-
poietin receptor (TPO-R) agonist, in 90